SCHEMBL30790488

SCHEMBL30790488

O=C(c1ccccc1-c1ccc(Cl)cc1)N1C2CNCC1C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
RAB9A P51151 1/20 0.42
TSHR P16473 1/20 0.40
RECQL P46063 1/20 0.40
MLNR O43193 1/20 0.40
CYP3A4 P08684 1/20 0.40
IDH1 O75874 1/20 0.38
HSD17B3 P37058 1/20 0.38
CHRM1 P11229 4/20 0.37
CHRM2 P08172 2/20 0.37
CHRM3 P20309 2/20 0.37
CHRM4 P08173 1/20 0.37
AGTR2 P50052 1/20 0.36
KDM1A O60341 1/20 0.36
SLC6A2 P23975 1/20 0.36
HCRTR1 O43613 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30790612 0.92 SLC6A4 (0.46) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL30790452 0.79 CHRNA4 (0.54) SLC6A4SLC6A3TSHRRECQLMLNR
SCHEMBL30789807 0.77 KDM1A (0.47) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL30789880 0.77 KDM1A (0.47) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL30790439 0.77 KDM1A (0.47) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL30790551 0.75 MLNR (0.49) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL30359152 0.75 MEN1 (0.46) LMNAALOX15TSHR
SCHEMBL32667651 0.74 RXFP1 (0.64) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL22192837 0.74 RXFP1 (0.64) SLC6A4SLC6A3NPC1LMNAALOX15
SCHEMBL30790460 0.73 SLC6A4 (0.43) SLC6A4SLC6A3NPC1LMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028326-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) 2026-01-29 US disclosed
WO-2024032689-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028326-A1 COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF CDR2, CYC1, CLN6 SLC6A4 2363/4885SLC6A3 1375/4885NPC1 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.